NEW YORK ( TheStreet) -- HCA Holdings ( HCA), Thermo Fisher ( TMO), Covidien ( COV), Mednax Inc. ( MD), Bio-rad Laboratories ( BIO), Pharmasset. ( VRUS), UnitedHealth Group ( UNH) and United Therapeutics Corporation ( UTHR) have average buying rating of 83%, according to a Bloomberg consensus.Teva Pharmaceutical Industries ( TEVA), a leading generic player, recently won U.S. anti-trust approval for a deal to acquire specialty drug maker Cephalon ( CEPH). In the preceding quarter, Thermo Fisher ( TMO), a serving science major, reported completing the acquisition of Phadia, a leader in blood tests, in a deal valued $3.5 billion, primarily to boost its presence in high-growth specialty diagnostic regions. Several pharma majors with strong balance sheets, relatively less leverage and higher cash generating capacities can consider acquisitions as the segment's valuations have declined in the last couple of months. We have identified eight health care stocks that, according to analysts, could outperform their peers and the broader market indices. These stocks have upside potential of 20% to 38% with a mean upside value of 30%. In contrast, pharma giants Johnson & Johnson ( JNJ), Abbott Laboratories ( ABT), Bristol Myers Squibb ( BMY) and Eli Lilly ( LLY) have upsides of -2% to 10%, according to analysts' estimates. These eight stocks are listed in ascending order of buy ratings.